AusperBio gets China CDE clearance to initiate phase III clinical trial of AHB-137 for chronic hepatitis B
AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (collectively AusperBio), a clinical-stage biotechnology company advancing targeted oligonucleotide therapies for chronic hepatitis B (CHB) functional cure, announced that the China Center for …